Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours Β· Estimated delivery Aug 11 - Aug 16
Secondary outcome measurements included reduction in body weight from baseline by at least 5% or 10% by week 26, changes in waist circumference, total cholesterol, HDL, LDL, VLDL, and triglycerides, and levels of different glycemic variables including HbA1C, fasting plasma glucose, fasting insulin, insulin resistance, and the functioning of beta-cells
Whitens and evens skin tone
It is engineered to bind with high affinity to three distinct receptor sites, creating a metabolic environment conducive to rapid fat oxidation and glycemic control
Factors such as medication dose, adherence, initial weight, and presence of diabetes can all influence your outcome
Tirzepatide (Mounjaro, Zepbound) targets GLP-1 and GIP, with a metabolic advantage that promotes fat breakdown while helping preserve muscle mass
doi:10.1056/NEJMoa2028198 8
